Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728052 | 0.85 | GSK3B (0.59) | SMN1; SMN2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL255269 | 0.83 | GSK3B (0.61) | SMN1; SMN2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL8980467 | 0.81 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL29185502 | 0.81 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL279440 | 0.81 | MAPK1 (0.63) | SMN1; SMN2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL28007433 | 0.80 | MAPT (0.62) | SMN1; SMN2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL2293183 | 0.80 | GSK3B (0.57) | ALDH1A1MEN1MAPTKMT2AMAPK1 | |
| SCHEMBL11510574 | 0.80 | GSK3B (0.71) | ALDH1A1MEN1KMT2AMAPK1GSK3B | |
| SCHEMBL12503662 | 0.80 | GSK3B (0.53) | SMN1; SMN2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL255479 | 0.79 | GSK3B (0.61) | ALDH1A1MEN1KMT2AMAPK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745823-A | Preparation method and application of compound | 武夷学院 | 2023-03-07 | — | — | CN | claimed |
| CN-108658777-A | A kind of synthetic method of paranitrobenzoic acid | 四川武胜春瑞医药化工有限公司 | 2018-10-16 | — | — | CN | claimed |
| CN-115745823-B | Preparation method and application of compound | 武夷学院 | 2024-02-23 | — | — | CN | disclosed |
| CN-115745823-A | Preparation method and application of compound | 武夷学院 | 2023-03-07 | — | — | CN | disclosed |
| CN-108658777-A | A kind of synthetic method of paranitrobenzoic acid | 四川武胜春瑞医药化工有限公司 | 2018-10-16 | — | — | CN | disclosed |
| US-20170121349-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2017-05-04 | — | — | US | disclosed |
| US-7592365-B2 | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-22 | — | — | US | disclosed |
| US-7592365-B2 | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-22 | — | — | US | disclosed |
| US-7592365-B2 | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-22 | — | — | US | disclosed |
| EP-1851198-B1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2008-12-31 | — | — | EP | disclosed |
| EP-1851198-B1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2008-12-31 | — | — | EP | disclosed |
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-10 | — | — | US | disclosed |
| CN-101115716-A | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA SA (FR) | 2008-01-30 | — | — | CN | disclosed |
| EP-1851198-A1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084996-A1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-08-17 | — | — | WO | disclosed |
| WO-1995004053-A1 | UREA AND THIOUREA DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA S.P.A. (IT) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | PRMT1, ADPRS, RRM2B | SMN1; SMN2 2756/4885ALDH1A1 282/4885MEN1 2028/4885 |
| US-20170121349-A1 | Anti-Infective Compounds | FNTB, LSS, PGLS | SMN1; SMN2 4810/4885ALDH1A1 1595/4885MEN1 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.